dm+d

46233009

Articles

Written Instruction for the administration of seasonal ‘flu vaccination

25 August 2021Advice on using written instructions for the administration of 'flu vaccinations to healthcare staff and written instruction templates 2021/22 are available.

Safety in Lactation: Vaccines and antisera

21 September 2020Although vaccines and toxoids (diphtheria and tetanus) are considered to be compatible with breastfeeding, their use should be limited to those situations where there is…

Can small volume intramuscular injections be given to patients taking oral anticoagulants?

17 September 2018This Medicines Q&A discusses the potential risks associated with the administration of small volume IM injections to patients taking oral anticoagulants. It has been partially…
Search Articles

Refrigerated Storage

Fluenz TetraAstraZeneca UK Ltd

AstraZeneca UK Ltd
Fluenz Tetra
Nasal Spray Suspension

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY

In the event of an inadvertent temperature excursion the following data may be used:
Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 12 hours at a temperature not above 25°C. If the vaccine has not been used after this 12 hour period, it should be discarded.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

See above
No
29 September 2021
London MI Service

Influvac sub-unit TetraViatris (Formerly Mylan)

Viatris (Formerly Mylan)
Influvac sub-unit Tetra
Suspension for injection in pre-filled syringe

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY

Contact Viatris in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Do not freeze

1 October 2021
London MI Service

Quadrivalent Influenza vaccine (Split virion, inactivated)Sanofi Pasteur

Sanofi Pasteur
Quadrivalent Influenza vaccine (Split virion, inactivated)
Suspension for injection in pre-filled syringe

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY

Contact Sanofi Pasteur in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

29 September 2021
London MI Service

Flucelvax Tetra Seqirus UK Ltd

Seqirus UK Ltd
Flucelvax Tetra
Suspension for injection in pre-filled syringe

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY

Contact Seqirus UK Ltd in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Do not freeze

30 September 2021
London MI Service

SupemtekSanofi Pasteur

Sanofi Pasteur
Supemtek
Solution for injection in pre-filled syringe

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY

Contact Sanofi Pasteur in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Do not freeze

29 September 2021
London MI Service

Fluad Tetra Seqirus UK Ltd

Seqirus UK Ltd
Fluad Tetra
Suspension for injection in pre-filled syringe

THIS ADVICE APPLIES FOR 2021/2022 INFLUENZA SEASON ONLY
Contact Seqirus UK Ltd in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

Do not freeze

1 October 2021
London MI Service

Lactation Safety Information

Yes
Inactivated (intramuscular or intradermal) or live attenuated (intranasal) vaccines
Live (attenuated) virus in the intranasal vaccine has been adapted to cold in order to replicate in the nasal passage. Survival highly unlikely at breast milk temperatures.
15 October 2018

New Medicines

Fluad TetraInfluenza prophylaxis in adults aged 65 years and older

Information

Fluad Tetra
Vaccine
Seqirus
Seqirus

Development and Regulatory status

Launched
Launched
None
September 2020
Sep 21Fluad Tetra suspension in pre-filled syringe price for 10 PFS = £118.80 [5].
Sep 20Company notes that the timing of approval was such that Fluad Tetra will not be available for use during this 2020/2021 influenza season. However, UK healthcare professionals can pre-order Fluad Tetra from 1st September 2020 for use during the 2021/2022 influenza season [4].
May 20Approved in EU [3].
Mar 20CHMP issues a positive opinion recommending approval of Fluad Tetra for prophylaxis of influenza in the elderly (65 years of age and older) [2].

Category

Contains inactivated influenza virus surface antigens from 4 different influenza virus strains (two A and two B subtypes). Also contains the adjuvant MF59C.1 (MF59), which is designed to increase and broaden the antigen-specific immune response
Worldwide, annual influenza epidemics result in about 90 million cases with approximately 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths, of which 28,000 to 111,500 occur in children [1].
Influenza prophylaxis in adults aged 65 years and older
Intramuscular

Evidence based evaluations

SupemtekInfluenza prophylaxis in adults

Information

Supemtek
Vaccine
Sanofi
Sanofi

Development and Regulatory status

Launched
Approved (Licensed)
Launched
April 2021
Apr 21Available in the UK. Price = 1x10 single dose pre-filled syringes cost £220.00 [5,6,7].
Nov 20Approved in EU and UK [4].
Sep 20Recommended for EU approval by CHMP - the full indication is "for active immunization for the prevention of influenza disease in adults. It should be used in accordance with official recommendations" [3].

Category

A quadrivalent entirely egg-free recombinant haemagglutinin vaccine produced in insect cells
Seroconversion rate in the UK every year is around 10% to 20%, and up to 15% develop symptomatic influenza; peak time for cases is December to March and average GP consultation rate is 50-300 cases per 100,000 population per week. While most people will recover, influenza is considered to be potentially responsible for excess winter deaths in most years. Current vaccine effectiveness is estimated at about 59% overall in adults [2].
Influenza prophylaxis in adults
Intramuscular

Evidence based evaluations

Influenza prevention in patients aged 65 years and above

Information

Vaccine
Novavax
Novavax

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Recombinant haemagglutinin nanoparticle-based seasonal influenza vaccine. Contains saponin-based Matrix-M adjuvant which stimulates long lasting antibody and cell-mediated immune responses.[3]
Up to 15% of the population can develop influenza in any year. There is a 10-20% seroconversion rate with or without symptoms. In an average year, there are 50-200 GP consultations for influenza or flu-like illnesses per 100,000 population per week.[1]
Influenza prevention in patients aged 65 years and above
Intramuscular

M-001Influenza A and B - universal vaccine against current and future strains

Information

M-001
Vaccine
BiondVax Pharmaceuticals
BiondVax Pharmaceuticals

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jan 21 Company 2020 annual report indicates that following negative PIII trial results, development of M-001 has been discontinued. The company "is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets". [5]

Category

M-001 induces cellular (CMI) and enhances humoral (priming effect) immune response to a broad range of influenza strains
Up to 15% of the population can develop influenza in any year. There is a 10-20% seroconversion rate with or without symptoms. In an average year, there are 50-200 GP consultations for influenza or flu-like illnesses per 100,000 population per week.[1]
Influenza A and B - universal vaccine against current and future strains
Parenteral

Trial or other data

Oct 20Topline results from PIII trial failed to meet primary or secondary endpoint. A statistically significant difference between vaccinated and placebo groups in reduction of flu illness or severity was not seen [4].